Drugs / PF-05161704
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01202266 | Aug → Dec 2010 | type 2 diabetes mellitus | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT01183715 | Jul → Sep 2010 | type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-05161704 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01202266 ↗ |
| Route | Oral | “oral dosing Suspensions administered twice daily for 14 days” NCT01202266 ↗ |